AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ergometrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ergot alkaloid derivatives | 1042 | 60-79-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | mg | O |
| 0.20 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.02 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,KDR,MAP2K6,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 38 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EIF2AK3,MAP2K6,MAP3K21,PDK1 | 7 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AB03 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| CHEBI has role | CHEBI:27026 | toxin |
| CHEBI has role | CHEBI:33295 | diagnostic agent |
| CHEBI has role | CHEBI:36063 | oxytocic |
| CHEBI has role | CHEBI:76946 | fungal metabolite |
Related Drugs by ATC class:
G02AB Ergot alkaloids 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Postabortal Hemorrhage | indication | ||
| Incomplete miscarriage | off-label use | 156072005 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Pregnancy-induced hypertension | contraindication | 48194001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sepsis syndrome | contraindication | 238150007 | |
| Pregnancy, function | contraindication | 289908002 | |
| Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.56 | acidic |
| pKa2 | 13.5 | acidic |
| pKa3 | 7.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(1A) dopamine receptor | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
| D(2) dopamine receptor | GPCR | EC50 | 8 | WOMBAT-PK | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.20 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.33 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | EC50 | 8.50 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 8.58 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.96 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 8.82 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.88 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.71 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | EC50 | 9 | WOMBAT-PK | |||||
| Alpha-1B adrenergic receptor | GPCR | Kd | 6.37 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | EC50 | 7.70 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 8.89 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 8.09 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | AGONIST | Ki | 8.50 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4017426 | VUID |
| N0000179118 | NUI |
| D01163 | KEGG_DRUG |
| 129-51-1 | SECONDARY_CAS_RN |
| 4017426 | VANDF |
| 4022085 | VANDF |
| C0014704 | UMLSCUI |
| CHEBI:4822 | CHEBI |
| CHEMBL119443 | ChEMBL_ID |
| CHEMBL1213135 | ChEMBL_ID |
| DB01253 | DRUGBANK_ID |
| 443884 | PUBCHEM_CID |
| 148 | IUPHAR_LIGAND_ID |
| 24313 | RXNORM |
| 3591 | MMSL |
| 4673 | MMSL |
| d00586 | MMSL |
| 001305 | NDDF |
| 004940 | NDDF |
| 126071000 | SNOMEDCT_US |
| 126072007 | SNOMEDCT_US |
| 54541002 | SNOMEDCT_US |
| D004874 | MESH_DESCRIPTOR_UI |
| 390 | INN_ID |
| YMH3D0ZJWV | UNII |
Pharmaceutical products:
None